PET/CT for Trop2 ADC Response Evaluation NSCLC

NCT07151898 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Xiamen University

Phase

Observational

Started

2025-05-01

Last updated

2025-09-03

Condition(s) studied

NSCLCTrop2PET/CT

Investigational drug(s) / intervention(s)

68Ga-MY6349 PET/CT

68Ga-MY6349 PET/CT: Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two and/or four cycles of Trop2-ADC therapy.

Study summary

To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in NSCLC patients.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * adult patients (aged 18 years or order) * histologically or cytologically confirmed metastatic NSCLC previously treated with systemic therapy, supported by imaging (e.g. CT, MRI), tumor markers, or pathology reports * presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 * willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Ability to provide written informed consent and, where applicable, assent in accordance with the requirements of the Clinical Research Ethics Committee Exclusion Criteria: * Evidence of significantly impaired hepatic or renal function * Estimated life expectancy of less than 3 months

Primary outcome measure(s)

The predictive value of series 68Ga-MY6349 PET/CT in patients with NSCLC who received Trop2-ADC therapy — 2025.5-2027.5
For 68Ga-MY6349 PET/CT parameter, the maximum standard uptake value (SUVmax) is measured by defining a region of interest (ROI) around the primary tumor. SUVmax values obtained at baseline and after two and/or four cycles of Trop2-ADC therapy were collected and analyzed in relation to treatment response.

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Xiamen University	Xiamen	Fujian	Recruiting

More The First Affiliated Hospital of Xiamen University trials in China

The Effect of Semaglutide on Bone Health Starting soon

Ultrasound Assessment of Fetal Growth Parameters Enrolling by invitation

Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC Recruiting

Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery Recruiting

Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients Recruiting

Other trials for the same condition

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer Recruiting

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases Recruiting

RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC Recruiting

Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy Starting soon

Perioperative Treatment Outcomes of Early NSCLC Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07151898 on ClinicalTrials.gov ↗ ← All trials in China